Your doctor can order a genetic test that could indicate whether or not you stand to benefit from Cymbalta. A number of studies have associated specific gene polymorphisms with antidepressant response.
Quote:
|
GeneSight Psychotropic is a genetic panel that provides information about genes that may affect a patient’s response to antidepressant and antipsychotic pharmacotherapy. According to the manufacturer’s website, following testing, the treating provider receives a report with the most common medications for the patient’s diagnosed condition categorized by cautionary level, along with a report of the patient’s genetic variants. Details are not provided about the algorithm used by the manufacturer to generate risk levels.
|
Source: HMSA Policy on Genetic Testing for Mental Health Conditions, effective date 7/1/2015
From
GeneSight Psychotropic's website:
Quote:
The GeneSight Psychotropic laboratory developed test analyzes how your genes affect the way your body may respond to FDA-approved medicines commonly prescribed to treat depression, anxiety, bipolar disease, schizophrenia or other behavioral health conditions.
The information from the GeneSight test can help your healthcare provider select the medicine(s) and dose(s) that are best suited to your condition and genetic makeup. Medicines that align well with your genes may work better with fewer side effects.
GeneSight is based on pharmacogenomics—the study of how genes affect a person’s response to medicines. This test was developed in the Assurex Health clinical laboratory and is based on patented technology licensed from two world renowned medical centers, Mayo Clinic and Cincinnati Children’s Hospital Medical Center, who continue to be research collaborators.
|
